Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

Berman PW, Murthy KK, Wrin T, Vennari JC, Cobb EK, Eastman DJ, Champe M, Nakamura GR, Davison D, Powell MF, Bussiere J, Francis DP, Matthews T, Gregory TJ, Obijeski JF.

J Infect Dis. 1996 Jan;173(1):52-9.

PMID:
8537682
2.

Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2.

el-Amad Z, Murthy KK, Higgins K, Cobb EK, Haigwood NL, Levy JA, Steimer KS.

AIDS. 1995 Dec;9(12):1313-22.

PMID:
8605050
3.

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

Girard M, Meignier B, Barré-Sinoussi F, Kieny MP, Matthews T, Muchmore E, Nara PL, Wei Q, Rimsky L, Weinhold K, et al.

J Virol. 1995 Oct;69(10):6239-48.

4.

HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.

Bruck C, Thiriart C, Fabry L, Francotte M, Pala P, Van Opstal O, Culp J, Rosenberg M, De Wilde M, Heidt P, Heeney J.

Vaccine. 1994 Sep;12(12):1141-8.

PMID:
7998425
5.

Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, Eichberg JW.

Nature. 1990 Jun 14;345(6276):622-5.

PMID:
2190095
6.

Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.

Haigwood NL, Nara PL, Brooks E, Van Nest GA, Ott G, Higgins KW, Dunlop N, Scandella CJ, Eichberg JW, Steimer KS.

J Virol. 1992 Jan;66(1):172-82.

7.

A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.

Mooij P, van der Kolk M, Bogers WM, ten Haaft PJ, Van Der Meide P, Almond N, Stott J, Deschamps M, Labbe D, Momin P, Voss G, Von Hoegen P, Bruck C, Heeney JL.

AIDS. 1998 Mar 26;12(5):F15-22.

PMID:
9543435
8.

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.

Berman PW, Matthews TJ, Riddle L, Champe M, Hobbs MR, Nakamura GR, Mercer J, Eastman DJ, Lucas C, Langlois AJ, et al.

J Virol. 1992 Jul;66(7):4464-9.

9.

Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.

Robert-Guroff M, Kaur H, Patterson LJ, Leno M, Conley AJ, McKenna PM, Markham PD, Richardson E, Aldrich K, Arora K, Murty L, Carter L, Zolla-Pazner S, Sinangil F.

J Virol. 1998 Dec;72(12):10275-80.

10.

Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.

Girard M, van der Ryst E, Barré-Sinoussi F, Nara P, Tartaglia J, Paoletti E, Blondeau C, Jennings M, Verrier F, Meignier B, Fultz PN.

Virology. 1997 May 26;232(1):98-104.

11.

Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120.

Davis D, Donners H, Willems B, Lövgren-Bengtsson K, Akerblom L, Vanham G, Barnett S, Morein B, Heeney JL, van der Groen G.

Vaccine. 2004 Jan 26;22(5-6):747-54.

PMID:
14741168
12.

Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.

Lockey TD, Slobod KS, Caver TE, D'Costa S, Owens RJ, McClure HM, Compans RW, Hurwitz JL.

Immunol Res. 2000;21(1):7-21.

PMID:
10803879
13.

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS.

J Infect Dis. 1996 Feb;173(2):340-8.

PMID:
8568294
14.

Comparison of the immune response to recombinant gp120 in humans and chimpanzees.

Berman PW, Eastman DJ, Wilkes DM, Nakamura GR, Gregory TJ, Schwartz D, Gorse G, Belshe R, Clements ML, Byrn RA.

AIDS. 1994 May;8(5):591-601.

PMID:
7520248
15.

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.

Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Hsieh RH, Mestecky J, Zolla-Pazner S, Mascola J, Schwartz D, Siliciano R, Corey L, Wright PF, Belshe R, Dolin R, Jackson S, Xu S, Fast P, Walker MC, Stablein D, Excler JL, Tartaglia J, Paoletti E, et al.

J Infect Dis. 1998 May;177(5):1230-46.

PMID:
9593008
17.

Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.

Berman PW.

AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S277-89. Review.

PMID:
9814956
18.

Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.

Gibbs CJ Jr, Peters R, Gravell M, Johnson BK, Jensen FC, Carlo DJ, Salk J.

Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3348-52.

19.

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, Wild CT, Mascola JR, Stamatatos L.

J Virol. 2001 Jun;75(12):5526-40.

20.

Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

Buonaguro L, Racioppi L, Tornesello ML, Arra C, Visciano ML, Biryahwaho B, Sempala SD, Giraldo G, Buonaguro FM.

Antiviral Res. 2002 Jun;54(3):189-201.

PMID:
12062391

Supplemental Content

Support Center